Review
doi: 10.1161/01.CIR.0000100688.17280.E6.
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial
Affiliations
- PMID: 14609996
- DOI: 10.1161/01.CIR.0000100688.17280.E6
Item in Clipboard
Review
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial
Circulation.
.
No abstract available
Similar articles
-
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22. Circ Cardiovasc Qual Outcomes. 2009. PMID: 20031900 Clinical Trial.
-
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.Am J Cardiol. 2007 Dec 1;100(11):1659-64. doi: 10.1016/j.amjcard.2007.09.072. Epub 2007 Oct 24. Am J Cardiol. 2007. PMID: 18036365 Clinical Trial.
-
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?Am J Cardiol. 2006 Jan 16;97(2A):33A-41A. doi: 10.1016/j.amjcard.2005.11.014. Epub 2005 Dec 1. Am J Cardiol. 2006. PMID: 16442935 Review.
-
The JUPITER trial: How will it change clinical practice?Rev Cardiovasc Med. 2009 Spring;10(2):91-6. Rev Cardiovasc Med. 2009. PMID: 19593321 Review.
-
Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.J Am Coll Cardiol. 2009 Mar 17;53(11):931-5. doi: 10.1016/j.jacc.2008.12.010. J Am Coll Cardiol. 2009. PMID: 19281922 Clinical Trial.
Cited by
-
Statins for the primary prevention of venous thromboembolism.Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD014769. doi: 10.1002/14651858.CD014769.pub2. Cochrane Database Syst Rev. 2024. PMID: 39498835
-
A combined transcriptomics and proteomics approach reveals S100A4 as a potential biomarker for Graves' orbitopathy.Front Genet. 2024 Sep 18;15:1342205. doi: 10.3389/fgene.2024.1342205. eCollection 2024. Front Genet. 2024. PMID: 39359477 Free PMC article.
-
Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions.Biomedicines. 2024 Jul 26;12(8):1670. doi: 10.3390/biomedicines12081670. Biomedicines. 2024. PMID: 39200135 Free PMC article. Review.
-
Renoprotective Effect of Pitavastatin against TAA-Induced Renal Injury: Involvement of the miR-93/PTEN/AKT/mTOR Pathway.Adv Pharmacol Pharm Sci. 2024 Jan 23;2024:6681873. doi: 10.1155/2024/6681873. eCollection 2024. Adv Pharmacol Pharm Sci. 2024. PMID: 38293706 Free PMC article.
-
Impact of Donor Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Transplant Cell Ther. 2023 Nov;29(11):701.e1-701.e8. doi: 10.1016/j.jtct.2023.08.027. Epub 2023 Aug 30. Transplant Cell Ther. 2023. PMID: 37657769 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
